MedTrace Logo

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT01401322 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-11-28

Study results available
· View outcomes & findings →

Summary

Time-to-Progression (TTP)

Conditions

  • Leukemia
  • Relapsed Adult Acute Lymphocytic Leukemia

Interventions

DRUG

Lenalidomide

50 mg; po

Sponsors & Collaborators

Principal Investigators

  • Bruno Carneiro de Medeiros · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-01-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01401322 on ClinicalTrials.gov